Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives
Background: It is still uncertain whether Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor have synergistic effects on metastatic soft tissue sarcomas (STSs). The purpose of this study was to evaluate the safety and activity of nab-paclitaxe...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1335054/full |
| _version_ | 1797337248480362496 |
|---|---|
| author | Zhichao Tian Yushen Feng Yang Yang Xu Liu Guoxin Qu Yonghao Yang Xin Wang Jiaqiang Wang Peng Zhang Weitao Yao |
| author_facet | Zhichao Tian Yushen Feng Yang Yang Xu Liu Guoxin Qu Yonghao Yang Xin Wang Jiaqiang Wang Peng Zhang Weitao Yao |
| author_sort | Zhichao Tian |
| collection | DOAJ |
| description | Background: It is still uncertain whether Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor have synergistic effects on metastatic soft tissue sarcomas (STSs). The purpose of this study was to evaluate the safety and activity of nab-paclitaxel plus camrelizumab (a PD-1 inhibitor) in patients with advanced STS who had previously failed chemotherapy.Methods: In this single-center, open-label, single-arm phase II clinical trial, patients with advanced (unresectable or metastatic) STS who had previously failed chemotherapy received up to six cycles of nab-paclitaxel plus camrelizumab, whereas camrelizumab treatment was continued for up to 1 year. The median progression-free survival (PFS), objective response rate (ORR) and safety were collected and evaluated.Results: This trial included 40 patients (28 men and 12 women). The overall ORR was 22.5%, and the median PFS was 1.65 months (95% confidence interval [CI], 1.3–2.0 months). Patients with epithelioid sarcoma demonstrated a longer PFS compared with those with other histological subtypes (2.3 months vs. 1.5 months, respectively); however, this difference was not significant. Patients who had received only one line of previous chemotherapy had a significantly longer PFS compared with those who had undergone two or more lines of previous chemotherapy (2.8 months vs. 1.3 months, respectively, p = 0.046). In terms of safety, the toxicity of this combination therapy is mild and no serious adverse events have occurred.Conclusion: Nab-paclitaxel plus camrelizumab exhibited modest activity and mild toxicity in treating epithelioid sarcoma, angiosarcoma, and fibrosarcoma. The overall effectiveness of this treatment regimen for advanced STS is relatively low. Further research on combining nab-paclitaxel with effective drugs, including chemotherapy and targeted agents, for these specific STS subtypes is needed. |
| first_indexed | 2024-03-08T09:06:47Z |
| format | Article |
| id | doaj.art-cb0646cc43644c6f9033e39af93476db |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-08T09:06:47Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-cb0646cc43644c6f9033e39af93476db2024-02-01T04:40:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-02-011510.3389/fphar.2024.13350541335054Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectivesZhichao Tian0Yushen Feng1Yang Yang2Xu Liu3Guoxin Qu4Yonghao Yang5Xin Wang6Jiaqiang Wang7Peng Zhang8Weitao Yao9Department of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaSchool of medicine, Case Western Reserve University, Cleveland, OH, United StatesModern educational technology center, Henan University of Economics and Law, Zhengzhou, ChinaDepartment of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Bone and Soft Tissue, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, ChinaBackground: It is still uncertain whether Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor have synergistic effects on metastatic soft tissue sarcomas (STSs). The purpose of this study was to evaluate the safety and activity of nab-paclitaxel plus camrelizumab (a PD-1 inhibitor) in patients with advanced STS who had previously failed chemotherapy.Methods: In this single-center, open-label, single-arm phase II clinical trial, patients with advanced (unresectable or metastatic) STS who had previously failed chemotherapy received up to six cycles of nab-paclitaxel plus camrelizumab, whereas camrelizumab treatment was continued for up to 1 year. The median progression-free survival (PFS), objective response rate (ORR) and safety were collected and evaluated.Results: This trial included 40 patients (28 men and 12 women). The overall ORR was 22.5%, and the median PFS was 1.65 months (95% confidence interval [CI], 1.3–2.0 months). Patients with epithelioid sarcoma demonstrated a longer PFS compared with those with other histological subtypes (2.3 months vs. 1.5 months, respectively); however, this difference was not significant. Patients who had received only one line of previous chemotherapy had a significantly longer PFS compared with those who had undergone two or more lines of previous chemotherapy (2.8 months vs. 1.3 months, respectively, p = 0.046). In terms of safety, the toxicity of this combination therapy is mild and no serious adverse events have occurred.Conclusion: Nab-paclitaxel plus camrelizumab exhibited modest activity and mild toxicity in treating epithelioid sarcoma, angiosarcoma, and fibrosarcoma. The overall effectiveness of this treatment regimen for advanced STS is relatively low. Further research on combining nab-paclitaxel with effective drugs, including chemotherapy and targeted agents, for these specific STS subtypes is needed.https://www.frontiersin.org/articles/10.3389/fphar.2024.1335054/fullnab-paclitaxelcamrelizumabPD-1 inhibitorsarcomaimmunochemotherapy |
| spellingShingle | Zhichao Tian Yushen Feng Yang Yang Xu Liu Guoxin Qu Yonghao Yang Xin Wang Jiaqiang Wang Peng Zhang Weitao Yao Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives Frontiers in Pharmacology nab-paclitaxel camrelizumab PD-1 inhibitor sarcoma immunochemotherapy |
| title | Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives |
| title_full | Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives |
| title_fullStr | Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives |
| title_full_unstemmed | Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives |
| title_short | Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives |
| title_sort | combining nanoparticle albumin bound paclitaxel with camrelizumab in advanced soft tissue sarcoma activity safety and future perspectives |
| topic | nab-paclitaxel camrelizumab PD-1 inhibitor sarcoma immunochemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1335054/full |
| work_keys_str_mv | AT zhichaotian combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT yushenfeng combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT yangyang combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT xuliu combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT guoxinqu combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT yonghaoyang combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT xinwang combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT jiaqiangwang combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT pengzhang combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives AT weitaoyao combiningnanoparticlealbuminboundpaclitaxelwithcamrelizumabinadvancedsofttissuesarcomaactivitysafetyandfutureperspectives |